Clinical Endpoints Could Help Chronic Condition Drugs Switch
This article was originally published in The Tan Sheet
Companies attempting to switch a drug OTC for a chronic condition might have a stronger case if supported by data focusing on clinical endpoints rather than just markers, a workshop group surmised at the Consumer Healthcare Products Association Research & Scientific Development Conference in Washington, D.C. Oct. 28-29.
You may also be interested in...
QUESTRAN ADVISORY COMMITTEE EVENLY SPLIT ON OTC SUITABILITY after a reconsideration of Bristol-Myers Squibb's application to switch its Questran (cholestyramine) and Questran Light from prescription to OTC status for the treatment of hypercholesterolemia. At a May 13 meeting in Bethesda, Md., members of FDA's Nonprescription Drugs and Endocrinologic & Metabolic Drugs Advisory Committee voted five to five with one abstention on the suitability of the switch.
Finalization of a settlement between the Federal Trade Commission and Rexall Sundown regarding unsupported cellulite treatment claims for the firm's Cellasene dietary supplement hinges upon approval of two related class action settlements pending in California and Florida, according to FTC
Perrigo promotes in pricing, planning